keyword
MENU ▼
Read by QxMD icon Read
search

DMARDs

keyword
https://www.readbyqxmd.com/read/28109618/effects-of-dmards-on-citrullinated-peptide-autoantibody-levels-in-ra-patients-a-longitudinal-analysis
#1
Carolin Wunderlich, Isabelle Oliviera, Camille P Figueiredo, Juergen Rech, Georg Schett
OBJECTIVE: To study whether stable treatment with DMARDs affects anti-CCP2 antibody levels in patients with rheumatoid arthritis. METHODS: In this longitudinal observational study 100 RA patients were followed for anti-CCP2 IgG antibody (U/L) and total IgG level (mg/dL) every 6 months for a total period of 2.5 years. All patients received stable DMARD treatment during this period. Five groups comprising each 20 patients were analyzed as follows: (1) methotrexate (MTX) alone, (2) tumor necrosis factor inhibitors (TNFi), (3) tocilizumab (TCZ), (4) rituximab (RTX), and (5) abatacept (ABA)...
October 3, 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28102443/-new-options-for-the-practice-update-s1-s2-guidelines-on-rheumatoid-arthritis
#2
REVIEW
M Schneider
Guidelines are important tools for evidence-based pharmacological treatment of patients suffering from rheumatoid arthritis. Recommendations assist physicians in identifying the best form of treatment but ultimately, the final decision is based on joint participation by the patient and physician. Nowadays, general concepts, such as treat to target seem to be more important in rheumatoid arthritis than differencies between various drugs or drug classes. The universal recommendation to use methotrexate as the initial disease-modifying antirheumatic drug (DMARD) is driven more by economic reasons than by scientific data, which is not completely wrong but should be disclosed...
January 19, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28101910/a-practical-approach-to-vaccination-of-patients-with-autoimmune-inflammatory-rheumatic-diseases-in-australia
#3
REVIEW
Peter Kk Wong, Hanish Bagga, Claire Barrett, Paddy Hanrahan, Doug Johnson, Amel Katrib, Karin Leder, Mona Marabani, Peta Pentony, John Riordan, Ray White, Laurel Young
Autoimmune inflammatory rheumatic diseases (AIIRD) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are often complicated by infection, which results in significant morbidity and mortality. The increased risk of infection is probably due to a combination of immunosuppressive effects of the AIIRD, comorbidities, and the use of immunosuppressive conventional synthetic disease modifying anti-rheumatic drugs (DMARDS) and more recently, targeted synthetic DMARDS and biologic DMARDS which block specific pro-inflammatory enzymes, cytokines or cell types...
January 19, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28097393/comparative-efficacy-and-safety-of-baricitinib-2%C3%A2-mg-and-4%C3%A2-mg-in-patients-with-active-rheumatoid-arthritis-a%C3%A2-bayesian-network-meta-analysis-of-randomized-controlled-trials
#4
Y H Lee, S-C Bae
OBJECTIVE: This study aimed to assess the relative efficacy and safety of once-daily baricitinib 2 mg and 4 mg administration in patients with active rheumatoid arthritis (RA). METHODS: In this network meta-analysis, randomized controlled trials (RCTs) examining the efficacy and safety of baricitinib in patients with active RA were included. A Bayesian network meta-analysis was conducted to combine the direct and indirect evidence from the RCTs. RESULTS: Seven RCTs involving 3461 patients met the inclusion criteria...
January 17, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28089976/disease-characteristics-and-rheumatoid-arthritis-development-in-patients-with-early-undifferentiated-arthritis-a-2-year-followup-study
#5
Gina H Brinkmann, Ellen S Norli, Tore K Kvien, Anne J Haugen, Lars Grøvle, Halvor Nygaard, Olav Bjørneboe, Cathrine Thunem, Maria D Mjaavatten, Elisabeth Lie
OBJECTIVE: To examine the 2-year disease course in patients with undifferentiated arthritis (UA) focusing on fulfillment of the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) rheumatoid arthritis (RA) classification criteria. METHODS: Data were provided by the Norwegian Very Early Arthritis Clinic study, which included patients presenting with ≥ 1 swollen joint of ≤ 16 weeks' duration. UA was defined as patients not fulfilling the 2010 ACR/EULAR RA criteria and who did not have a clinical diagnosis other than RA at baseline...
January 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28089501/effectiveness-of-conventional-disease-modifying-antirheumatic-drugs-in-psoriatic-arthritis-a-systematic-review
#6
Jesús Maese, Petra Díaz Del Campo, Daniel Seoane-Mato, Mercedes Guerra, Juan D Cañete
BACKGROUND: Due to the clinical heterogeneity of psoriatic arthritis (PsA), recommendations have been developed by international groups to guide therapeutic decisions of the rheumatologist. The objective of the current systematic review (RS) was to evaluate the evidence of efficacy of disease-modifying antirheumatic drugs (DMARDs) in PsA. METHODS: Literature search in Medline, EMBASE, Cochrane Library, from 2008 to 2014. We included RS, randomized clinical trials and observational studies, in patients with PsA and an evaluation of efficiency of conventional DMARDs (methotrexate, sulfasalazine, leflunomide), according to the following outcomes: peripheral and axial symptoms; peripheral radiological damage; enthesitis according to power Doppler ultrasound or magnetic resonance imaging (enthesitis count before and after therapy); dactylitis; uveitis...
January 12, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28087505/2016-update-of-the-asas-eular-management-recommendations-for-axial-spondyloarthritis
#7
Désirée van der Heijde, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados, Floris van Gaalen, Pál Géher, Irene van der Horst-Bruinsma, Robert D Inman, Merryn Jongkees, Uta Kiltz, Tore K Kvien, Pedro M Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compàn, Salih Ozgocmen, Fernando M Pimentel-Santos, John Reveille, Martin Rudwaleit, Jochen Sieper, Percival Sampaio-Barros, Dieter Wiek, Jürgen Braun
To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009...
January 13, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28079512/long-term-treatment-response-in-rheumatoid-arthritis-patients-starting-adalimumab-or-etanercept-with-or-without-concomitant-methotrexate
#8
Merel J l'Ami, Eva L Kneepkens, Michael T Nurmohamed, Charlotte L M Krieckaert, Ingrid M Visman, Gert-Jan Wolbink
OBJECTIVES: To observe long-term clinical response and drug survival in a prospective two-year cohort study in rheumatoid arthritis (RA) patients starting adalimumab or etanercept treatment, with or without methotrexate (MTX), after failure of conventional DMARD therapy, including MTX. METHODS: Disease activity score of 28 joints (DAS28) and Health Assessment Questionnaire (HAQ) were collected of 873 consecutive RA patients, treated with adalimumab or etanercept, prospectively at baseline, 4, 16, 28, 40, 52, 78 and 104 weeks of biological therapy...
January 5, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28079500/efficacy-and-safety-of-tofacitinib-in-older-and-younger-patients-with-rheumatoid-arthritis
#9
Jeffrey R Curtis, Hendrik Schulze-Koops, Liza Takiya, Charles A Mebus, Ketti K Terry, Pinaki Biswas, Thomas V Jones
OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We evaluated the efficacy and safety of tofacitinib 5 or 10 mg twice daily (BID), in patients with moderate to severe RA, aged ≥65 and <65 years. METHODS: Data were pooled from five Phase 3 trials and, separately, from two open-label long-term extension (LTE) studies (data cut-off April, 2012). Patients received tofacitinib, or placebo (Phase 3 only), with/without conventional synthetic DMARDs (mainly methotrexate)...
January 4, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28065486/biologic-disease-modifying-antirheumatic-drug-attributes-in-the-first-lines-of-treatment-of-rheumatoid-arthritis-2015-acordar-project
#10
Santiago Muñoz-Fernández, María Sagrario Bustabad Reyes, Jaime Calvo Alén, Manuel Castaño Sánchez, Eugenio Chamizo Carmona, Héctor Corominas, Nagore Fernández-Llanio Comella, María Cristina Hidalgo Calleja, José Javier Pérez Venegas, José Manuel Rodríguez Heredia, Susana María Romero Yuste, Virginia Ruiz-Esquide Torino
OBJECTIVE: To date, between 17% and 35% of patients with rheumatoid arthritis (RA) do not respond as expected to the initial biological therapy. The objective of this project is to recognize and weigh the attributes of biologic DMARD (bDMARD) to identify the most appropriate for each case, in the first lines of treatment of RA (after inadequate response to at least one synthetic DMARD or previous bDMARD). METHODS: To recognize the possible attributes that could define the bDMARD, we performed a systematic search of the literature that recognized the possible attributes involving general aspects, pharmacology, efficacy, safety, management, and cost...
January 3, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28058499/-rheumatoid-arthritis
#11
REVIEW
D Aletaha, A Kerschbaumer
Therapy reduction in rheumatoid arthritis (RA) is still a challenge for physicians as well as for patients. Effective therapy with subsequent achievement of low disease activity or even remission is achievable for numerous patients using currently available treatment options. Therapy discontinuation has therefore become a hot topic and the risk of exacerbation of well-controlled RA must be weighed against the medical and economic benefits of reducing or even discontinuing therapy. This article gives a review of data regarding tapering of therapy in RA, focusing on conventional disease-modifying antirheumatic drug (DMARD) monotherapy, reduction of conventional therapy under continuing therapy with biologics and discontinuation of biologics...
January 5, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28053390/effectiveness-of-arthroscopic-elbow-synovectomy-in-rheumatoid-arthritis-patients-long-term-follow-up-of-clinical-and-functional-outcomes
#12
Vivek Shankar, Pankaj Sharma, Ravi Mittal, Samarth Mittal, Uma Kumar, Shivanand Gamanagatti
OBJECTIVE: To determine the long-term clinical and functional results of arthroscopic elbow synovectomy in rheumatoid arthritis patients with refractory elbow synovitis in terms of improvement in pain, function, and active range of motion (AROM) or arc of motion. METHOD: Fifteen rheumatoid elbows in 13 patients, not responding to DMARD therapy and with radiological changes not more than Larsen grade 3 were taken, who underwent arthroscopic elbow synovectomy. The main outcome measured in forms of Mayo Elbow Performance Scale (MEPS) score, measurement of pain using a Visual Analogue Scale (VAS), radiological angles of elbow, disease activity score (DAS-28), arc of motions (AOM) and complications, which were assessed at follow-up periods of 6 months, 24 months, and 30 months...
October 2016: Journal of Clinical Orthopaedics and Trauma
https://www.readbyqxmd.com/read/28040332/rheumatoid-arthritis-seems-to-have-dmard-treatment-decision-influenced-by-fibromyalgia
#13
Rafael Mendonça da Silva Chakr, Claiton Brenol, Aline Ranzolin, Amanda Bernardes, Ana Paula Dalosto, Giovani Ferrari, Stephanie Scalco, Vanessa Olszewski, Charles Kohem, Odirlei Monticielo, João Carlos T Brenol, Ricardo M Xavier
OBJECTIVE: To compare DMARD use in patients with and without FM over time, including overtreatment and undertreatment rates in both groups. METHODS: A prospective cohort study with patients attending an RA outpatient clinic was conducted. Participants were consecutively recruited between March 2006 and June 2007 and were followed through December 2013. Data on DMARD use (prevalences, doses and escalation rates), DAS28, HAQ and radiographic progression were compared among RA patients with FM and without FM...
December 18, 2016: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/28028156/patients-preferences-and-economic-considerations-play-an-important-role-in-treatment-decisions-a-discrete-choice-experiment-among-rheumatologists
#14
Monika Hifinger, Mickael Hiligsmann, Sofia Ramiro, Johan L Severens, Bruno Fautrel, Verity Watson, Annelies Boonen
OBJECTIVE: To evaluate to what extent rheumatologists consider economic aspects and patients' preferences when choosing drug treatments in patients with active RA. METHODS: In a discrete choice experiment, rheumatologists were asked to choose between two unlabelled drug treatment options for a hypothetical RA patient with moderate disease activity who failed two synthetic DMARDs. Attributes and levels of drug treatments were selected based on existing literature, rheumatologists' opinion and expert consensus...
January 2017: Rheumatology
https://www.readbyqxmd.com/read/28028155/abatacept-reduces-disease-activity-and-ultrasound-power-doppler-in-acpa-negative-undifferentiated-arthritis-a-proof-of-concept-clinical-and-imaging-study
#15
Maya H Buch, Elizabeth M A Hensor, Chadi Rakieh, Jane E Freeston, Edward Middleton, Sarah Horton, Sudipto Das, Charles Peterfy, Ai Lyn Tan, Richard J Wakefield, Paul Emery
OBJECTIVES: No proven treatment exists for ACPA-negative undifferentiated arthritis (UA). The aim of this study was to evaluate whether abatacept is effective in treating poor prognosis, ACPA-negative UA, including its effect on power Doppler on US (PDUS). METHODS: A proof-of-concept, open-label, prospective study of 20 patients with DMARD-naïve, ACPA-negative UA (⩾2 joint synovitis) and PDUS ⩾ 1 with clinical and 20-joint US (grey scale/PDUS) assessments at baseline, 6, 12, 18 and 24 months...
January 2017: Rheumatology
https://www.readbyqxmd.com/read/28013211/effect-of-anti-tnf-and-conventional-synthetic-disease-modifying-anti-rheumatic-drug-treatment-on-work-disability-and-clinical-outcome-in-a-multicentre-observational-cohort-study-of-psoriatic-arthritis
#16
William Tillett, Gavin Shaddick, Amelia Jobling, Ayman Askari, Annie Cooper, Paul Creamer, Gavin Clunie, Philip S Helliwell, Jana James, Lesley Kay, Eleanor Korendowych, Suzanne Lane, Jonathon Packham, Ragai Shaban, Matthew L Thomas, Lyn Williamson, Neil McHugh
OBJECTIVE: To determine the effect of medical treatment on work disability in patients with active PsA in a real-world setting. METHODS: Four hundred patients with active PsA commencing or switching to anti-TNF or conventional synthetic DMARD (csDMARD) were recruited to a multicentre UK prospective observational cohort study. Work disability was measured using the work productivity and activity-specific health problem instrument and peripheral joint activity was measured with the disease activity in PsA composite measure...
December 24, 2016: Rheumatology
https://www.readbyqxmd.com/read/28013201/risk-of-serious-adverse-effects-of-biological-and-targeted-drugs-in-patients-with-rheumatoid-arthritis-a-systematic-review-meta-analysis
#17
Simon Tarp, Daniel Eric Furst, Maarten Boers, George Luta, Henning Bliddal, Ulrik Tarp, Karsten Heller Asmussen, Birgitte Brock, Anna Dossing, Tanja Schjødt Jørgensen, Steffen Thirstrup, Robin Christensen
OBJECTIVES: To determine possible differences in serious adverse effects among the 10 currently approved biological and targeted synthetic DMARDs (b/ts-DMARDs) for RA. METHODS: Systematic review in bibliographic databases, trial registries and websites of regulatory agencies identified randomized trials of approved b/ts-DMARDs for RA. Network meta-analyses using mixed-effects Poisson regression models were conducted to calculate rate ratios for serious adverse events (SAEs) and deaths between each of the 10 drugs and control (i...
December 24, 2016: Rheumatology
https://www.readbyqxmd.com/read/28013198/effect-of-tocilizumab-on-neutrophils-in-adult-patients-with-rheumatoid-arthritis-pooled-analysis-of-data-from-phase-3-and-4-clinical-trials
#18
Robert J Moots, Anthony Sebba, William Rigby, Andrew Ostor, Benjamin Porter-Brown, Francis Donaldson, Sophie Dimonaco, Andrea Rubbert-Roth, Ronald van Vollenhoven, Mark C Genovese
OBJECTIVES: To investigate changes in neutrophil count and occurrences of infection in RA patients treated with the IL-6 receptor-α inhibitor tocilizumab (TCZ). METHODS: Data were pooled from patients who received i.v. TCZ (4 mg/kg + MTX, 8 mg/kg ± DMARDs, 10 mg/kg) or placebo + DMARDs in phase 3/4 clinical trials, long-term extensions or a pharmacology study. Neutrophil counts were measured routinely according to the Common Toxicity Criteria for Adverse Events grades; TCZ dosing was adjusted if necessary...
December 24, 2016: Rheumatology
https://www.readbyqxmd.com/read/28013193/medication-use-among-pregnant-women-with-systemic-lupus-erythematosus-and-general-population-comparators
#19
Kristin Palmsten, Julia F Simard, Christina D Chambers, Elizabeth V Arkema
OBJECTIVE: The aim was to characterize SLE medication trends before, during and after pregnancy and to compare other commonly used medications during SLE pregnancies with non-SLE pregnancies. METHODS: Women with pregnancies ending in live birth or stillbirth were identified from the Swedish Medical Birth Register (2006-12). National registers were used to identify women with prevalent SLE during pregnancy and a sample without SLE and to identify prescription medications dispensed from 3 months pre-pregnancy until 6 months postpartum...
December 24, 2016: Rheumatology
https://www.readbyqxmd.com/read/28011918/hepatitis-b-virus-reactivation-in-rheumatoid-arthritis-patients-undergoing-biologics-treatment
#20
Ming-Han Chen, Ming-Huang Chen, Chun-Yu Liu, Chang-Youh Tsai, De-Feng Huang, Hsiao-Yi Lin, Mei-Hsuan Lee, Yi-Hsiang Huang
BACKGROUND: Immunosuppressants can induce hepatitis B virus(HBV) reactivation, however, informative data regarding the risk of different immunosuppressive regimens including biologics on HBV reactivation(HBVr) among patients with rheumatoid arthritis(RA) is unsettled. METHODS: Among 2334 RA patients who had available HBsAg data, 123 patients positive for hepatitis B surface antigen(HBsAg) without receiving anti-HBV prophylaxis were enrolled. These patients undergoing varied mono- or combination immunosuppressive therapy, including 36 receiving biological disease-modifying antirheumatic drugs(bDMARDs)...
December 23, 2016: Journal of Infectious Diseases
keyword
keyword
86203
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"